Morand EF - Search Results

1

Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.

Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Morand EF, Nikpour M; Asia-Pacific Lupus Collaboration. Golder V, et al. Among authors: morand ef. Arthritis Res Ther. 2016 Nov 9;18(1):260. doi: 10.1186/s13075-016-1163-2. Arthritis Res Ther. 2016. PMID: 27829463 Free PMC article.

2

Fibromyalgia syndrome and disease activity in systemic lupus erythematosus.

Morand EF, Miller MH, Whittingham S, Littlejohn GO. Morand EF, et al. Lupus. 1994 Jun;3(3):187-91. doi: 10.1177/096120339400300310. Lupus. 1994. PMID: 7951304

3

Body composition in systemic lupus erythematosus.

Kipen Y, Strauss BJ, Morand EF. Kipen Y, et al. Among authors: morand ef. Br J Rheumatol. 1998 May;37(5):514-9. doi: 10.1093/rheumatology/37.5.514. Br J Rheumatol. 1998. PMID: 9651078

4

Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus.

Kipen Y, Briganti EM, Strauss BJ, Littlejohn GO, Morand EF. Kipen Y, et al. Among authors: morand ef. Rheumatology (Oxford). 1999 Jan;38(1):59-65. doi: 10.1093/rheumatology/38.1.59. Rheumatology (Oxford). 1999. PMID: 10334684

5

Churg-Strauss syndrome: the use of cyclophosphamide in mononeuritis.

Hoi AY, Morand EF. Hoi AY, et al. Among authors: morand ef. Rheumatology (Oxford). 2003 Feb;42(2):390-1. doi: 10.1093/rheumatology/keg067. Rheumatology (Oxford). 2003. PMID: 12595649 No abstract available.

6

Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?

Hoi AY, Morand EF, Leech M. Hoi AY, et al. Among authors: morand ef. Immunol Cell Biol. 2003 Oct;81(5):367-73. doi: 10.1046/j.1440-1711.2003.01183.x. Immunol Cell Biol. 2003. PMID: 12969324 Review.

7

Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice.

Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, James WG, Kitching AR, Morand EF. Hoi AY, et al. Among authors: morand ef. J Immunol. 2006 Oct 15;177(8):5687-96. doi: 10.4049/jimmunol.177.8.5687. J Immunol. 2006. PMID: 17015758

8

Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases.

Hoi AY, Iskander MN, Morand EF. Hoi AY, et al. Among authors: morand ef. Inflamm Allergy Drug Targets. 2007 Sep;6(3):183-90. doi: 10.2174/187152807781696455. Inflamm Allergy Drug Targets. 2007. PMID: 17897055 Review.

9

Smooth muscle myopathy as an underrecognized manifestation of active systemic lupus erythematosus.

Ngian GS, Naidoo P, Morand EF, Hoi AY. Ngian GS, et al. Among authors: morand ef. Intern Med J. 2011 Jun;41(6):495-8. doi: 10.1111/j.1445-5994.2011.02505.x. Intern Med J. 2011. PMID: 21707895

10

Lymphocytes from systemic lupus erythematosus patients display increased spreading on VCAM-1, an effect associated with active renal involvement.

Cheng Q, Hoi A, Hickey MJ, Morand EF. Cheng Q, et al. Among authors: morand ef. Lupus. 2012 May;21(6):632-41. doi: 10.1177/0961203312436860. Epub 2012 Feb 16. Lupus. 2012. PMID: 22345121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters